<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">To determine the prognostic value of the Hh-activated stromal gene signature (HSGS), we examined its impact on overall survival using The Cancer Genome Atlas (TCGA) breast invasive carcinoma cohort
 <sup>
  <xref ref-type="bibr" rid="CR19">19</xref>
 </sup>. The HSGS was not predictive of patient outcome in the unstratified patient cohort (Fig. 
 <xref rid="Fig2" ref-type="fig">2d</xref>) but was associated with significantly lower patient overall survival uniquely in the basal breast cancer subtype, where Hh ligand is most frequently overexpressed
 <sup>
  <xref ref-type="bibr" rid="CR6">6</xref>
 </sup> (Hazard ratio = 9.7 (1.9−48.2); 
 <italic>P</italic> &lt; 0.001; Fig. 
 <xref rid="Fig2" ref-type="fig">2d</xref>).
</p>
